Security
URGN · UroGen Pharma Ltd.
URGNNASDAQCommon stockCurrentCIK 1668243Updated Sep 29, 2026
URGN price & chart
Loading TradingView…
NASDAQ:URGN on TradingView ↗In the news
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm News provided by The Schall Law Firm Jun 16, 2025, 10:38 ET Share this article Share to X Share this article Share to X LOS ANGELES , June 16, 2025 /PRNewswire/ -- The Schall Law Firm , a nat ↗
UroGen Pharma Ltd. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 28, 2025 to Discuss Your Rights - URGN News provided by Levi & Korsinsky, LLP Jun 13, 2025, 05:45 ET Share this article Share to X Share this article Share to X NEW YORK , June 13, 2025 /PRNewswire/ -- Levi ↗
Recent filings
144 filing
4 filing
Other Events
Items 8.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
4 filing
4 filing
Material Modification to Rights of Security Holders · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 3.03, 5.02, 5.07, 9.01
Other Events
Items 8.01
ARS filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 200,455,000Source | 285,711,000Source | 178,311,000Source | 135,619,000Source |
| Property, Plant and Equipment, NetUSD | 637,000Source | 655,000Source | 689,000Source | 1,297,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 110,745,000Source | 171,987,000Source | 95,002,000Source | 55,408,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 33,082,000Source | 20,302,000Source | 15,443,000Source | 12,704,000Source |
| Inventory, NetUSD | 16,464,000Source | 9,227,000Source | 5,673,000Source | 4,325,000Source |
| Assets, CurrentUSD | 186,024,000Source | 276,135,000Source | 169,186,000Source | 128,907,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 14,672,000Source | 8,845,000Source | 10,281,000Source | 11,101,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,080,000Source | 849,000Source | 1,671,000Source | 2,452,000Source |
| Other Assets, NoncurrentUSD | 5,161,000Source | 589,000Source | 2,038,000Source | 2,740,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 305,929,000Source | 294,514,000Source | 243,523,000Source | 224,980,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 133,000Source | 115,000Source | 89,000Source | 63,000Source |
| Retained Earnings (Accumulated Deficit)USD | -959,716,000Source | -806,222,000Source | -679,348,000Source | -577,104,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 19,000Source | 56,000Source | 12,000Source | -107,000Source |
| Stockholders' Equity Attributable to ParentUSD | -105,474,000Source | -8,803,000Source | -65,212,000Source | -89,361,000Source |
| Additional Paid in Capital, Common StockUSD | 854,090,000Source | 797,248,000Source | 614,035,000Source | 487,787,000Source |
| Liabilities and EquityUSD | 200,455,000Source | 285,711,000Source | 178,311,000Source | 135,619,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 46,418,000Source | 45,949,000Source | 31,212,000Source | 23,916,000Source |
| Operating Lease, Liability, CurrentUSD | 481,000Source | 785,000Source | — | — |
| Accounts Payable, CurrentUSD | 12,137,000Source | 10,931,000Source | 6,514,000Source | 5,527,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,646,000Source | 58,000Source | 844,000Source | 1,586,000Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 120,500,000Source | 241,700,000Source | 141,500,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 122,210,000Source | 121,734,000Source | 98,551,000Source | 97,537,000Source |
| Short-term InvestmentsUSD | 49,310,000Source | 110,672,000Source | 56,160,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 307,000Source | 329,000Source | 802,000Source | 924,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 11,959,000Source | 13,108,000Source | 9,343,000Source | 10,580,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 12,780,000Source | 4,859,000Source | 2,739,000Source | 987,000Source |
| Increase (Decrease) in InventoriesUSD | 7,237,000Source | 3,554,000Source | 1,348,000Source | 362,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -162,444,000Source | -96,766,000Source | -76,376,000Source | -87,559,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 61,558,000Source | -20,613,000Source | -953,000Source | 1,060,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 289,000Source | 295,000Source | 194,000Source | 254,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 39,918,000Source | 194,619,000Source | 116,931,000Source | 97,134,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -60,968,000Source | 77,240,000Source | 39,602,000Source | 10,635,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 3,000,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 11,959,000Source | 13,108,000Source | 9,343,000Source | 10,580,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 120,500,000Source | 241,700,000Source | 141,500,000Source | — |
| Income Tax Expense (Benefit)USD | 78,000Source | 2,832,000Source | 3,920,000Source | 1,755,000Source |
| Inventory Write-downUSD | — | — | 0Source | 870,000Source |
| Investment Income, InterestUSD | 5,965,000Source | 8,901,000Source | 2,641,000Source | 938,000Source |
| Net Income (Loss) Attributable to ParentUSD | -153,494,000Source | -126,874,000Source | -102,244,000Source | -109,783,000Source |
| Nonoperating Income (Expense)USD | -670,000Source | -229,000Source | 838,000Source | 72,000Source |
| Operating Lease, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Proceeds from Issuance of Common StockUSD | 39,801,000Source | 151,169,000Source | 67,358,000Source | — |
| Proceeds from Issuance of Long-term DebtUSD | 0Source | 24,488,000Source | 0Source | 95,783,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 139,247,000Source | 107,705,000Source | 49,073,000Source | 64,323,000Source |
| Proceeds from Stock Options ExercisedUSD | 1,972,000Source | 321,000Source | 873,000Source | 1,511,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 109,788,000Source | 90,398,000Source | 82,713,000Source | 64,357,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 155,097,000Source | 121,154,000Source | 93,274,000Source | 82,838,000Source |
| Operating Income (Loss)USD | -124,863,000Source | -96,782,000Source | -65,536,000Source | -79,041,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -153,416,000Source | -124,042,000Source | -98,324,000Source | -108,028,000Source |
| Income Tax Expense (Benefit)USD | 78,000Source | 2,832,000Source | 3,920,000Source | 1,755,000Source |
| Net Income (Loss) Attributable to ParentUSD | -153,494,000Source | -126,874,000Source | -102,244,000Source | -109,783,000Source |
| Earnings Per Share, BasicUSD per share | -3.19Source | -2.96Source | -3.55Source | -4.81Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 48,116,098Source | 42,876,737Source | 28,834,303Source | 22,806,812Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 78,000Source | 2,832,000Source | 3,920,000Source | 1,755,000Source |
| Gross ProfitUSD | 97,341,000Source | 81,517,000Source | 73,352,000Source | 56,703,000Source |
| Interest and Other IncomeUSD | 5,295,000Source | 8,672,000Source | 3,479,000Source | 1,010,000Source |
| Investment Income, InterestUSD | 5,965,000Source | 8,901,000Source | 2,641,000Source | 938,000Source |
| Nonoperating Income (Expense)USD | -670,000Source | -229,000Source | 838,000Source | 72,000Source |
| Research and Development ExpenseUSD | 67,107,000Source | 57,145,000Source | 45,614,000Source | 52,906,000Source |
Filing attachments
d903812dex991.htm · 8-K · 2025-01-14
EX-99.1 2 d903812dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Developing Innovative Medicines to Treat Urothelial Cancers January 2025 Disclaimers This investor presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the potential of UroGen’s proprietary technology to enhance proven and novel medicines and deliver them aligned with the way urologists practice; the estimated addressable patie…
Read attachment ↗